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The main drawbacks are mentioned by a lower percent of 
participants: 
·        There are no institutional support and resources to 
make the analysis (71% of RO, 56% of MP and 33% of RTT). 
·        Time needed (86% of RO, 44% of MP and 50% of RTT). 
·        Very few indicate that it cannot detect the safety weak 
points (14% of RO), results are qualitative and subjective 
(17% of RTT) or that the risk analysis has not the depth 
needed (33% of MP). 
The software used (SEVRRA) was considered as a tool easy to 
use that facilitates the analysis by 71% of RO, 89% of MP and 
67% of RTT. 
Conclusions: The risk matrix is a proven tool for risk analysis 
in radiotherapy.  To implement a risk methodology among 
radiotherapy professionals it is very important that everyone 
who takes part in the process is involved in the risk analysis. 
The working group needs basic training before they can start 
it and assistance from risk analysis experts. 
Training a reduced number of radiotherapy centers, that can 
eventually act as reference centers at local level, is a 
feasible and effective way of spreading the use of these 
techniques at national level. 
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Introduction: Patient safety in radiotherapy is a 
comparatively new discipline that has rapidly risen to star 
status. This rise began in the late 1990s, with eye-opening 
reports documenting the scale of harm caused by medical 
errors. In 2010, the New York Times published a series of 
articles on medical errors elevating the awareness of 
accidents in radiotherapy. Safe radiotherapy requires a multi-
disciplinary comprehensive approach to assure that an 
adequate safety system is in place.  One aspect of a robust 
safety system is the identification of near misses and errors 
that occur in radiotherapy.  The use of an incident learning 
system can capture data that can be used to identify 
weakness in safety and provide the institution with 
information in the use of effective safety barriers. 
Institutions can also look at the potential for harm and 
identify safety infrastructure needs using prospective risk 
analysis such as Failure Mode and Effects Analysis (FMEA). 
These types of analytical tools assist in understanding the 
adequacy of the safety system by addressing the potential for 
errors, the frequency of the errors and the severity of the 
errors. Both reporting and learning systems and prospective 
analysis have value in patient safety, but to elevate their 
effectiveness, the institution should consider looking at 
industry wide activities and results.  Benchmarking can be 
used to compare one institution’s safety system and 
performance metrics to industry standards.  The IAEA Safety 
in Radiation Oncology (SAFRON) Incident Learning system can 
provide both institutional data and global data on potential 
errors.  The system is in the process of implementing a 
prospective risk analysis option that will allow the participant 
to address the likelihood of an event to happen at their 
institution based on initiating events, barriers and 
consequences. 
Purpose/Objective: Provide information of the tools that are 
available to improve safety in radiotherapy, including: 
·   retrospective studies to include incident learning systems, 
·   prospective studies to identify potential for harm, and 
·   use of benchmarking to evaluate safety systems against 
institutional standards. 
Material/methods: Lecture to include demonstration of the 
effectiveness in reducing radiotherapy incidents by 
evaluating past incidents, prospective risk analysis and 
benchmarking. 
Results: Participants will have knowledge on the use of these 
safety tools that can be incorporated into the clinical 
environment and knowledge on how to evaluate their safety 
system. 
Conclusion: A robust safety system in radiotherapy requires a 
multi-disciplinary comprehensive approach that includes 
evaluating events within the institution, evaluating the 
potential for harm and comparing these activities to 
institutional standards in radiotherapy.  This can best be 
accomplished by participating in an incident learning system, 
conducting prospective risk analysis and benchmarking these 
results. 
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The first recorded use of heat to treat cancer was made some 
5000 years ago, thus making it one of the oldest cancer 
therapies known. But, when using heat as a single agent 
therapy, tumour control is only likely when very high thermal 
ablation temperatures are achieved. At lower temperatures 
in the hyperthermia range (typically temperatures of up to 
around 43OC) tumour control is not possible. As a result, 
hyperthermia is often considered an experimental treatment 
with no realistic future in clinical cancer therapy. This is 
wrong. Although hyperthermia per se is probably only useful 
in palliative situations and has no role to play in the curative 
treatment of human tumours, there is definitive evidence 
that when hyperthermia is combined with more conventional 
therapies significant improvements in clinical outcome are 
possible. This is especially true for the combination of 
hyperthermia and radiation, and in fact, hyperthermia is 
probably one of the most effective radiation sensitizers 
known. In this presentation, we will review the pre-clinical 
studies establishing the rationale for how hyperthermia 
should be combined with conventional therapies and present 
an update of the clinical results demonstrating the clear 
benefit of such combination treatments in patients with 
specific types of cancer. In addition, we will discuss what 
approaches are now being applied to further improve the 
efficacy of hyperthermia when combined with more 
conventional therapies. 
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For the future success of clinical hyperthermia in multimodal 
cancer therapy specifically in combination with radiotherapy 
a concentrated and coordinated effort in all domains is 
needed. Input must come from biology (e.g. 
thermoradiobiology, thermoimmunonology), medical physics 
(e.g. noninvasive thermometry, treatment planning), 
engineering (e.g. novel hardware for intensity modulated 
hyperthermia and image guided hyperthermia), IT (e.g. 
optimization and synergy of RT and HT-workflow); and clinics 
(phase I/II study in large animal with spontaneous tumors and 
for human patients with novel technology, 
multicenter/international randomized phase III studies for 
common tumours with stringent QA criteria). 
Key issues are: 
1.       Why, despite a sound thermoradiobiological rationale 
is clinical implementation of HT so slow?  
2.        Why is innovation and progress in the development of 
timely hardware and software technology so slow, 
specifically if compared to the recent progress in radiation 
oncology technology?  
3.       Why did hyperthermia not get a better integration into 
clinical protocols using state of the art radiation therapy 
technology?  
4.       What are the promises of thermoablative procedures 
like HIFU, RFA, or nanotechnology based hyperthermia 
compared to classical regional (capacitive or radiative) 
hyperthermia used as physical radio sensitizer? 
An international coordinated effort is needed with active 
participation of all stakeholders. Local institutional 
innovations are desperately needed from interested industrial 
partners, academic centers focusing on technology 
development and academic centers focusing on novel clinical 
trial design. This could provide optimal synergism and pave 
the way toward implementation of oncology hyperthermia as 
a standard treatment modality within multimodal cancer 
therapy. 
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Hyperthermia methods can be subdivided into local, 
locoregional and whole body heating, and in different 
temperature ranges either aiming for direct ablation 
(T>55°C, only for local heating) or for radiosensitization and 
chemosensitization (39°C<T<43°C, all three categories). The 
application of hyperthermia should always be guided by 
sufficient thermometry during treatment to ensure that the 
intended thermal dose is given to the entire target region. 
This is challenging due to tissue and blood flow 
heterogeneities which can affect the uniformity of the 
thermal dose distribution. 
Achieving a uniform temperature rise of 39-42°C is 
straightforward for whole body heating techniques, but more 
challenging for local and locoregional hyperthermia. Most 
clinical hyperthermia equipment uses radiofrequency (RF) 
and microwave (MW) antennas for local and locoregional 
heating of tumors. Deep seated tumors are heated with 
phased arrays of RF/MW antennas. The frequencies of 70-
150MHz used for heating deep seated tumors result in heating 
of the tumor and a large margin around the tumor. The trend 
is to increase both the frequency and the number of antennas 
in order to reduce the focus size and thus achieve more 
selective tumor heating. Temperature measurements are 
performed with a limited number of invasive temperature 
probes, these are now increasingly supplemented with non-
invasive temperature measurements using MRI and other 
techniques which yield a 3-D image of the temperature 
distribution. 
Tumor ablation is achieved with invasive interstitial RF, MW 
and ultrasound (US) techniques. A more recent non-invasive 
technique is High Intensity Focused Ultrasound (HIFU) 
combined with non-invasive MRI thermometry. HIFU is 
capable of focusing heating to regions <1cm, the use of HIFU 
to achieve uniform heating of a large region to 40-43°C is 
presently investigated.  
Reliable hyperthermia treatment planning is important for 
pre-treatment planning, adaptive planning during treatment 
and for reconstruction of the given thermal dose distribution 
after treatment. A challenge for hyperthermia treatment 
planning is to model both the energy absorption in the tissue 
and the bio heat transfer by tissue blood flow, and the latter 
may also change during treatment. The latest planning 
systems are capable of fast and high resolution computations, 
sufficiently fast for real time computation during treatment, 
e.g. to adapt settings in response to changing blood flow 
values. 
Conclusion: hyperthermia equipment is increasingly capable 
of providing a well-controlled dose distribution similar to 
standards in radiation oncology. This well-controlled dose 
distribution is essential in achieving optimal clinical results. 
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Hyperthermia (HT) serves as a safe adjuvant treatment to 
radiotherapy in order to enhance its clinical results 
(radiosensitisation). It causes usually no or minimal injury to 
normal tissues. The best approach is to deliver hyperthermia 
and radiation simultaneously, which is difficult in common 
practice. The above is supported with extensive preclinical 
data and a number of randomized clinical trials concerning 
mainly combination of different types of hyperthermia 
treatment with standard external beam radiotherapy of 
specific types of cancer. Unfortunately, brachytherapy based 
HT treatment is quite poorly investigated and these data are 
scarce. Nevertheless, a short subjective literature review will 
be presented. Then, some possible clinical applications will 
be discussed, e.g. superficial or interstitial local/regional HT 
